{'fraction_non_alphanumeric': 0.031462585034013606, 'fraction_numerical': 0.025510204081632654, 'mean_word_length': 5.467032967032967, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long‐term treatment with heparin dramatically reduced massive proteinuria in patients with advanced IgA nephropathy

Previous studies indicated that heparin administration attenuates proteinuria and retards progression of glomerulosclerosis in several experimental models. Since heparin treatment has been shown to reduce albuminuria in patients with overt diabetic nephropathy (Lancet 1995), we examined the effect of heparin on proteinuria and renal function in patients with advanced IgA nephropathy. Fourteen patients with IgA nephropathy who have more than 30% of global sclerosis (GS) and/ or tubulointerstitial lesion (TI) were recruited for the present study. Nine patients were treated with continuous intravenous infusion of heparin (10 000-15 000 unit/24 h) for 8 weeks, ACE inhibitors (ACEI) and/or angiotensin I1 receptor antagonists (AHA) and dypiridamole for 24 weeks (Group 1, five males, four females, mean age 40 years). Five patients were treated with ACEI/AIIA and dypiridamole for 24 weeks (Group 2, four males, one female, mean age 41 years). The effect of these drugs on proteinuria was compared between both groups. There were no significant difference